Corporate ActionJul 30, 2026, 04:33 PM
Ocugen Seeks Shareholder Approval to Increase Authorized Shares by 250M
AI Summary
Ocugen is seeking shareholder approval to amend its charter to increase the number of authorized common shares by 250,000,000, raising the total to 640,000,000. This increase is crucial for future equity financings, strategic transactions, and equity incentive plans, and is also required to allow for the conversion of $130.0 million in convertible senior notes into shares. While the company acknowledges potential dilution for existing shareholders, it emphasizes the importance of this flexibility for long-term growth and to avoid cash settlement of the notes.
Key Highlights
- Stockholders to vote on increasing authorized common shares by 250,000,000 to 640,000,000.
- Current outstanding shares are 339,110,401 as of July 27, 2026.
- Increase is required to enable conversion of $130.0 million convertible senior notes into shares.
- Failure to approve means convertible notes will be settled in cash, not shares.
- CEO Dr. Musunuri's PSUs/stock options may settle in cash if not approved by Dec 31, 2026.
- Special Meeting of Stockholders scheduled for September 21, 2026.
- Board unanimously recommends voting FOR the share increase proposal.
Price Impact
More from OCGN